PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
17.97%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
18.43%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
58.16%
EPS growth of 58.16% while AVXL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
58.16%
Diluted EPS growth of 58.16% while AVXL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
96.23%
Share count expansion well above AVXL's 6.54%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
96.23%
Diluted share count expanding well above AVXL's 6.54%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.94%
OCF growth above 1.5x AVXL's 8.07%. David Dodd would confirm a clear edge in underlying cash generation.
22.94%
FCF growth above 1.5x AVXL's 8.07%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-567.72%
Negative 10Y OCF/share CAGR while AVXL stands at 54.85%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.81%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
89.23%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-636.46%
Negative 10Y net income/share CAGR while AVXL is at 61.94%. Joel Greenblatt sees a major red flag in long-term profit erosion.
93.35%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
88.82%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
2271.09%
10Y equity/share CAGR above 1.5x AVXL's 139.78%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-76.58%
Negative 5Y equity/share growth while AVXL is at 29.44%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-2.44%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
756.79%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
-16.19%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.49%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-24.67%
We cut SG&A while AVXL invests at 27.23%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.